Rocket Pharmaceuticals (RCKT)
Develops gene therapies for rare immune and cardiovascular disorders.
$3.43
After-hours close+0.08 (+2.24%)
At close$3.36(+2.60%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 91.52% | 100.46M shares | |
|---|---|---|---|
| 185 holders · as of Jun 30, 2026 | |||
| Insiders | 3.61% | 3.96M shares | |
| 20 holders · as of Sep 15, 2026 | |||
| Other | 4.87% | 5.35M shares | |
| remainder | |||
109.77M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
185 holders · 100.46M shares · 19 new positions · 90 increased · 65 reduced · 37 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 17.69M | 16.11% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 9.92M | 9.04% | +2.09M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 5.81M | 5.29% | +1.12M | Aug 13, 2026 |
| Citigroup Inc | 4.87M | 4.43% | −242.2K | Aug 3, 2026 |
| Marshall Wace, LLP | 4.03M | 3.67% | +990.5K | Aug 13, 2026 |
| Millennium Management LLC | 4.00M | 3.64% | +882.2K | Aug 14, 2026 |
| Newtyn Management, LLC | 4.00M | 3.64% | +834.1K | Aug 14, 2026 |
| Maverick Capital Ltd | 3.92M | 3.57% | +356.6K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vanguard Portfolio Management | 5.35% | 5.85M | 13G | Jul 31, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 11, 2026 | Martin Wilsonofficer: General Counsel | Sale | 75,364 | $3.40 | 598,489 |
| Aug 18, 2026 | Martin Wilsonofficer: General Counsel | Sale | 631 | $3.38 | 673,853 |
| Aug 18, 2026 | Gaurav Shahofficer: CEO | Sale | 2,293 | $3.38 | 1,056,594 |
| Aug 13, 2026 | Gaurav Shahofficer: CEO | Sale | 2,837 | $3.38 | 1,058,887 |
| Aug 13, 2026 | Martin Wilsonofficer: General Counsel | Sale | 3,493 | $3.38 | 674,484 |
| Aug 11, 2026 | Sarbani Chaudhuriofficer: See Remarks | Sale | 4,701 | $3.50 | 262,809 |
| Aug 11, 2026 | Christopher James Stevensofficer: Chief Operating Officer | Sale | 36,658 | $3.50 | 505,784 |
| May 21, 2026 | Gaurav Shahofficer: CEO | Sale | 55,684 | $3.09 | 1,061,724 |
| May 19, 2026 | John Militelloofficer: See Remarks | Sale | 384 | $3.01 | 89,780 |
| May 19, 2026 | Martin Wilsonofficer: General Counsel | Sale | 662 | $3.01 | 677,977 |
House and Senate disclosures
Not reported.